{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:47:05Z","timestamp":1772617625881,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/bmt.2011.261","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T12:27:19Z","timestamp":1329136039000},"page":"1350-1355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1038","volume":"47","author":[{"given":"M H","family":"Jagasia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G D","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B J","family":"Bolwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G G","family":"Laport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T B","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Durrant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Szer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-G","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Lizambri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E K","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,13]]},"reference":[{"key":"BFbmt2011261_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrc2804","volume":"10","author":"RR Jenq","year":"2010","unstructured":"Jenq RR, van den Brink MR . Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10: 213\u2013221.","journal-title":"Nat Rev Cancer"},{"key":"BFbmt2011261_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1750-1172-2-35","volume":"2","author":"DA Jacobsohn","year":"2007","unstructured":"Jacobsohn DA, Vogelsang GB . Acute graft versus host disease. Orphanet J Rare Dis 2007; 2: 35.","journal-title":"Orphanet J Rare Dis"},{"key":"BFbmt2011261_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00520-006-0176-9","volume":"15","author":"M Vera-Llonch","year":"2007","unstructured":"Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S . Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2007; 15: 491\u2013496.","journal-title":"Support Care Cancer"},{"key":"BFbmt2011261_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/bmt.2008.373","volume":"43","author":"R Ram","year":"2009","unstructured":"Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O . Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009; 43: 643\u2013653.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011261_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383\u2013388.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011261_CR6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood.V94.2.825","volume":"94","author":"OI Krijanovski","year":"1999","unstructured":"Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825\u2013831.","journal-title":"Blood"},{"key":"BFbmt2011261_CR7","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood.V92.10.3960","volume":"92","author":"A Panoskaltsis-Mortari","year":"1998","unstructured":"Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR . Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960\u20133967.","journal-title":"Blood"},{"key":"BFbmt2011261_CR8","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood.V96.13.4350","volume":"96","author":"A Panoskaltsis-Mortari","year":"2000","unstructured":"Panoskaltsis-Mortari A, Taylor PA, Rubin JS, Uren A, Welniak LA, Murphy WJ et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000; 96: 4350\u20134356.","journal-title":"Blood"},{"key":"BFbmt2011261_CR9","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1056\/NEJMoa040125","volume":"351","author":"R Spielberger","year":"2004","unstructured":"Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590\u20132598.","journal-title":"N Engl J Med"},{"key":"BFbmt2011261_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.bmt.1705846","volume":"40","author":"B Nasilowska-Adamska","year":"2007","unstructured":"Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983\u2013988.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011261_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/bmt.2008.157","volume":"42","author":"S Langner","year":"2008","unstructured":"Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275\u2013279.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011261_CR12","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1182\/blood-2006-04-017780","volume":"108","author":"BR Blazar","year":"2006","unstructured":"Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. Phase 1\/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216\u20133222.","journal-title":"Blood"},{"key":"BFbmt2011261_CR13","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.bbmt.2008.06.013","volume":"14","author":"JE Levine","year":"2008","unstructured":"Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ . Long-term follow-up of a phase I\/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant 2008; 14: 1017\u20131021.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2011261_CR14","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011261_CR15","unstructured":"World Health Organization. A Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva, 1979."},{"key":"BFbmt2011261_CR16","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1200\/JCO.2005.02.8340","volume":"24","author":"PJ Stiff","year":"2006","unstructured":"Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186\u20135193.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2011261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011261","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T14:35:23Z","timestamp":1648046123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2011261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,13]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFbmt2011261"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.261","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,13]]},"assertion":[{"value":"20 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MGC and RL are employees of Amgen Inc. and hold stock in Amgen Inc. MHJ and EKW were compensated by Amgen Inc. for consultation during study planning and for providing central review of GVHD scores.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}